A Effect of Bortezomib administration on autophagic cell death in colorectal cancer cells

Abstract

Colon cancer is the most common cancer type after breast cancer and prostate cancer in humans. Radiotherapy, chemotherapy, and surgical methods are commonly used treatments of colon cancer. In this study, Bortezomib, a proteasome inhibitor, investigated cell deaths regarding the suppression of cell proliferation that involves stimulation of DNA repairers, apoptosis, and autophagy. Bortezomib (Velcade) was applied and incubated to colorectal cancer cells (HT-29) for 24 hours at different concentrations (10 nm, 20 nm, and 40 nm). MTT was used to determine the viability, and anti-Beclin-1 and anti-LC3 immune reactive cells were determined using the immunocytochemical method. In the study findings, it has been determined that Beclin-1 immune reactive cells were found as higher in 10nM and 40nM concentrations of Bortezomib than other groups. In the immunocytochemical anti-LC3 evaluation, the immune reactive cell density was the highest at 40 nM concentration of Bortezomib, and this value decreased due to the decrease in the concentrations. In this study has been concluded that in light of the findings, the treatment of Bortezomib leads to an increase in levels of LC3 and Beclin-1 and activates autophagy in colon cancer cells.